The role of cannabinoids in benign urological disease as it relates to both basic science and clinical practice: A Systematic Review
BAUS ePoster online library. Taylor C. 11/11/20; 304105; P13-4
Mr. Charles Taylor
Mr. Charles Taylor
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)
The current role of cannabinoids in chronic pain related urological pathologies and the extent to which cannabinoids have a place in the future of urological practice – a systematic review

Taylor C1, Birch B2
1Southampton University Hospital, United Kingdom
2University Hospitals Southampton NHS FT, Faculty of Medicine, University of Southampton, Southampton General Hospital, United Kingdom

Introduction:
Many urological pathologies are associated with chronic pain and opioids have long played a fundamental role in their analgesia. However alternative methods to ameliorate pain are increasingly sought after. There is a growing amount of literature suggesting cannabinoids may fill this role.

Aims:
The present review aims to outline, from a urological perspective, the endocannabinoid system's function, distribution and potential pharmacological points of intervention. It aims to provide a detailed compendium illustrating how cannabinoids are currently used in painful urological conditions and to highlight the most promising cannabinoid treatments.

Methods:
The following bibliographic databases were searched: PubMed, Ovid MEDLINE, The Cochrane Library, EMBASE, Web of Science, Mednar and OpenGrey. 4 additional pathology specific searches were conducted. Searches were supplemented by a hand search of urological journals. Unpublished relevant reviews on PROSPERO were contacted. A total 68 papers were included in the review. The quality of papers was assessed via the CASP, CEBM and Cochrane Appraisal Checklists.

Results:
This review summarises several high-quality studies that demonstrate the promising therapeutic potential of cannabinoids especially with respect to, neurogenic bladder dysfunction (clinical studies), prostatic malignancy (cell line studies) and interstitial cystitis/bladder pain syndrome (animal model studies).

Conclusion:
It is evident that cannabinoids have the potential to be used as therapeutic agents in a plethora of urological conditions, but before the clinical potential of these agents can be exploited, high quality evidence based clinical trials must be conducted and cannabinoids must be standardised and treated like any other pharmaceutical agent.
The current role of cannabinoids in chronic pain related urological pathologies and the extent to which cannabinoids have a place in the future of urological practice – a systematic review

Taylor C1, Birch B2
1Southampton University Hospital, United Kingdom
2University Hospitals Southampton NHS FT, Faculty of Medicine, University of Southampton, Southampton General Hospital, United Kingdom

Introduction:
Many urological pathologies are associated with chronic pain and opioids have long played a fundamental role in their analgesia. However alternative methods to ameliorate pain are increasingly sought after. There is a growing amount of literature suggesting cannabinoids may fill this role.

Aims:
The present review aims to outline, from a urological perspective, the endocannabinoid system's function, distribution and potential pharmacological points of intervention. It aims to provide a detailed compendium illustrating how cannabinoids are currently used in painful urological conditions and to highlight the most promising cannabinoid treatments.

Methods:
The following bibliographic databases were searched: PubMed, Ovid MEDLINE, The Cochrane Library, EMBASE, Web of Science, Mednar and OpenGrey. 4 additional pathology specific searches were conducted. Searches were supplemented by a hand search of urological journals. Unpublished relevant reviews on PROSPERO were contacted. A total 68 papers were included in the review. The quality of papers was assessed via the CASP, CEBM and Cochrane Appraisal Checklists.

Results:
This review summarises several high-quality studies that demonstrate the promising therapeutic potential of cannabinoids especially with respect to, neurogenic bladder dysfunction (clinical studies), prostatic malignancy (cell line studies) and interstitial cystitis/bladder pain syndrome (animal model studies).

Conclusion:
It is evident that cannabinoids have the potential to be used as therapeutic agents in a plethora of urological conditions, but before the clinical potential of these agents can be exploited, high quality evidence based clinical trials must be conducted and cannabinoids must be standardised and treated like any other pharmaceutical agent.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies